Literature DB >> 24136102

Relative influence of heritability, environment and genetics on serum sclerostin.

A L Kuipers1, Y Zhang, S Yu, C M Kammerer, C S Nestlerode, Y Chu, C H Bunker, A L Patrick, V W Wheeler, I Miljkovic, J M Zmuda.   

Abstract

SUMMARY: We determined factors associated with serum sclerostin in 446 Afro-Caribbean family members. Age, weight, sex, diabetes and kidney function were associated with sclerostin. Sclerostin was heritable, and nine SNPs in the SOST gene region were associated with sclerostin. Variation in serum sclerostin is a heritable factor that is determined by both genetic and environmental factors.
INTRODUCTION: Sclerostin, encoded by the SOST gene, is a Wnt inhibitor that regulates bone mineralization and is a candidate gene locus for osteoporosis. However, little is known about the genetic and non-genetic sources of inter-individual variation in serum sclerostin levels.
METHODS: Serum sclerostin was measured in 446 Afro-Caribbean men and women aged 18+ from seven large, multigenerational families (mean family size, 64; 3,840 relative pairs). Thirty-six common single nucleotide polymorphisms (SNP) were genotyped within a 100 kb region encompassing the gene encoding sclerostin (SOST). Genetic and non-genetic factors were tested for association with serum sclerostin.
RESULTS: Mean serum sclerostin was 41.3 pmol/l and was greater in men than in women (P < 0.05). Factors associated with higher serum sclerostin were increased age and body weight, male sex, diabetes and decreased glomerular filtration rate, which collectively accounted for 25.4 % of its variation. Residual genetic heritability of serum sclerostin was 0.393 (P < 0.0001). Nine SNPs reached nominal significance with sclerostin. Three of those nine SNPs represented independent association signals (rs851056, rs41455049 and rs9909172), which accounted for 7.8 % of the phenotypic variation in sclerostin, although none of these SNPs surpassed a Bonferroni correction for multiple comparisons.
CONCLUSIONS: Serum sclerostin is a heritable trait that is also determined by environmental factors including age, sex, adiposity, diabetes and kidney function. Three independent common SNPs within the SOST region may collectively account for a significant proportion of the variation in serum sclerostin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24136102      PMCID: PMC3948173          DOI: 10.1007/s00198-013-2517-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  44 in total

1.  An evaluation of the variance components approach: type I error, power and size of the estimated effect.

Authors:  Yin Yao Shugart; Jeffrey R O'Connell; Alexander F Wilson
Journal:  Eur J Hum Genet       Date:  2002-02       Impact factor: 4.246

Review 2.  Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.

Authors:  Hua Zhu Ke; William G Richards; Xiaodong Li; Michael S Ominsky
Journal:  Endocr Rev       Date:  2012-06-20       Impact factor: 19.871

3.  Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus.

Authors:  Antonia García-Martín; Pedro Rozas-Moreno; Rebeca Reyes-García; Sonia Morales-Santana; Beatriz García-Fontana; José A García-Salcedo; Manuel Muñoz-Torres
Journal:  J Clin Endocrinol Metab       Date:  2011-10-26       Impact factor: 5.958

4.  Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes.

Authors:  Luigi Gennari; Daniela Merlotti; Roberto Valenti; Elena Ceccarelli; Martina Ruvio; Maria G Pietrini; Cosimo Capodarca; Maria Beatrice Franci; Maria Stella Campagna; Anna Calabrò; Dorica Cataldo; Konstantinos Stolakis; Francesco Dotta; Ranuccio Nuti
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

5.  Association of circulating sclerostin levels with fat mass and metabolic disease--related markers in Japanese postmenopausal women.

Authors:  Tomohiko Urano; Masataka Shiraki; Yasuyoshi Ouchi; Satoshi Inoue
Journal:  J Clin Endocrinol Metab       Date:  2012-05-25       Impact factor: 5.958

6.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).

Authors:  W Balemans; M Ebeling; N Patel; E Van Hul; P Olson; M Dioszegi; C Lacza; W Wuyts; J Van Den Ende; P Willems; A F Paes-Alves; S Hill; M Bueno; F J Ramos; P Tacconi; F G Dikkers; C Stratakis; K Lindpaintner; B Vickery; D Foernzler; W Van Hul
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

7.  Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.

Authors:  S Thambiah; R Roplekar; P Manghat; I Fogelman; W D Fraser; D Goldsmith; Geeta Hampson
Journal:  Calcif Tissue Int       Date:  2012-04-21       Impact factor: 4.333

8.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

9.  Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease.

Authors:  W Balemans; N Patel; M Ebeling; E Van Hul; W Wuyts; C Lacza; M Dioszegi; F G Dikkers; P Hildering; P J Willems; J B G M Verheij; K Lindpaintner; B Vickery; D Foernzler; W Van Hul
Journal:  J Med Genet       Date:  2002-02       Impact factor: 6.318

10.  A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.

Authors:  Karen Staehling-Hampton; Sean Proll; Bryan W Paeper; Lei Zhao; Patrick Charmley; Analisa Brown; Jessica C Gardner; David Galas; Randall C Schatzman; Peter Beighton; Socrates Papapoulos; Herman Hamersma; Mary E Brunkow
Journal:  Am J Med Genet       Date:  2002-06-15
View more
  9 in total

1.  Bone metabolism in patients with anorexia nervosa and amenorrhoea.

Authors:  L Idolazzi; M El Ghoch; R Dalle Grave; P V Bazzani; S Calugi; S Fassio; C Caimmi; O Viapiana; F Bertoldo; V Braga; M Rossini; D Gatti
Journal:  Eat Weight Disord       Date:  2016-10-27       Impact factor: 4.652

2.  Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.

Authors:  Luca Idolazzi; Angelo Fassio; Gaia Tripi; Vania Braga; Ombretta Viapiana; Giovanni Adami; Maurizio Rossini; Davide Gatti
Journal:  Clin Rheumatol       Date:  2017-01-05       Impact factor: 2.980

3.  Relationship Between Sclerostin (SOST) Expression and Genetic Loci rs851056, rs1230399 Polymorphisms and Bone Mineral Density in Postmenopausal Women with Type 2 Diabetes in Xinjiang.

Authors:  Jun Li; YanXia Ren; SiYuan Li; JiaJia Li
Journal:  Diabetes Metab Syndr Obes       Date:  2021-11-04       Impact factor: 3.168

Review 4.  The Role of Systemic Filtrating Organs in Aging and Their Potential in Rejuvenation Strategies.

Authors:  Amal Kassab; Nasser Rizk; Satya Prakash
Journal:  Int J Mol Sci       Date:  2022-04-14       Impact factor: 6.208

Review 5.  Sclerostin: From Molecule to Clinical Biomarker.

Authors:  Ahmed Omran; Diana Atanasova; Filip Landgren; Per Magnusson
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 6.  Sex steroid actions in male bone.

Authors:  Dirk Vanderschueren; Michaël R Laurent; Frank Claessens; Evelien Gielen; Marie K Lagerquist; Liesbeth Vandenput; Anna E Börjesson; Claes Ohlsson
Journal:  Endocr Rev       Date:  2014-09-09       Impact factor: 19.871

7.  Quantitative genetics of circulating Dickkopf-related protein 1 (DKK1) in community-based sample of UK twins.

Authors:  J Prakash; F M K Williams; S Trofimov; G Surdulescu; T Spector; G Livshits
Journal:  Osteoporos Int       Date:  2016-01-13       Impact factor: 4.507

8.  Circulating SIRT1 and Sclerostin Correlates with Bone Status in Young Women with Different Degrees of Adiposity.

Authors:  Rossella Tozzi; Davide Masi; Fiammetta Cipriani; Savina Contini; Elena Gangitano; Maria Elena Spoltore; Ilaria Barchetta; Sabrina Basciani; Mikiko Watanabe; Enke Baldini; Salvatore Ulisse; Carla Lubrano; Lucio Gnessi; Stefania Mariani
Journal:  Nutrients       Date:  2022-02-25       Impact factor: 5.717

9.  Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.

Authors:  Kristyna Brabnikova-Maresova; Katerina Jarosova; Karel Pavelka; Jan J Stepan
Journal:  Arthritis Res Ther       Date:  2014-10-04       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.